Leqembi

News

Leqembi sales grow again after subcutaneous approvals

Biogen/Eisai's Alzheimer's drug Leqembi continued to grow in Q2, driven by a new subcutaneous version, but fell a little short of expectations.

News

FDA clears at-home start dose for Alzheimer's drug Leqembi

The FDA has cleared Eisai and Biogen's Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits.

News

Eisai, Biogen face delay to subcutaneous Leqembi

Eisai and Biogen are facing a delay in the FDA review of injectable Leqembi for initial dosing in Alzheimer's, viewed as a key growth driver.

News

Most patients "won't see benefit" with Alzheimer's drugs

A review of clinical data on amyloid-targeting Alzheimer's therapies has found absent or trivial efficacy, but is facing pushback from some experts.

News

Appeal finds NICE must reconsider Alzheimer's drugs

Lilly and Eisai's bid to secure NHS coverage of their Alzheimer's therapies has entered a new phase, after an appeal of last year's rejection by NICE.

News

Leqembi starts to deliver for Eisai and Biogen

Three years after its first launch in the US, there are signs that Biogen and Eisai's Alzheimer's Leqembi therapy is gathering sales momentum.

Leqembi sales grow again after subcutaneous approvals

FDA clears at-home start dose for Alzheimer's drug Leqembi

Eisai, Biogen face delay to subcutaneous Leqembi

Most patients "won't see benefit" with Alzheimer's drugs

Appeal finds NICE must reconsider Alzheimer's drugs

Leqembi starts to deliver for Eisai and Biogen

Jazz builds in epilepsy with $1.3bn Actio acquisition

Discover a new era of healthcare panel engagement: Grounded ...

Leqembi

Editor's Picks